| Code | 0867D | ||||||||||
| MA number | 44/0066/19-S | ||||||||||
| Product Form: | tbl 100x0,75 mg (fľ.PE) | ||||||||||
| MA Status: | R - Valid Marketing Authorisation | ||||||||||
| Type of procedure: | Decentralised | ||||||||||
| MAH, country: | Nordic Group B.V., Netherland | ||||||||||
| Therapeutic Class: | 44 - CYTOSTATICA | ||||||||||
| ATC: |
|
||||||||||
| Shelf life: | 36 | ||||||||||
| Route of admin.: | Oral use |
| Prescription Status: | Medicinal product subject to restricted medical prescription. |
| Legal basis: | Article 10(3) hybrid application |
| MA issued: | 12.03.2019 |
| Validity: | 12.03.2024 |
| PIL: |
PIL_Anagrelid Nordic 0,75 mg tablety_06/2020.doc.doc
|
| SPC: |
SPC_Anagrelid Nordic 0,75 mg tablety_06/2020.doc.doc
|
| Safety feature | Yes |
| Data update: | 25.03.2019 |
